# Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee

> **NCT03529942** · PHASE3 · COMPLETED · sponsor: **Pacira Pharmaceuticals, Inc** · enrollment: 129 (actual)

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **DRUG:** FX006 32 mg

## Key facts

- **NCT ID:** NCT03529942
- **Lead sponsor:** Pacira Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-24
- **Primary completion:** 2019-11-08
- **Final completion:** 2020-03-09
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2024-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03529942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03529942, "Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03529942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*